Lacosamide Strides

Lacosamide, the active ingredient in Lacosamide Strides, is an anticonvulsant presented as an oral tablet for oral use. It treats partial‑onset seizures and broader epilepsy syndromes in both adult and pediatric patients requiring adjunctive therapy. It is indicated for patients whose seizures are not adequately controlled by other antiepileptic drugs.

GNH USA supplies Lacosamide Strides as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union quality standards and is manufactured under strict GMP conditions.

Lacosamide is used in the management of seizure disorders within the epilepsy therapeutic pathway.

- Partial‑onset seizures: reduces frequency of focal seizures when added to existing therapy. - Focal epilepsy: provides adjunctive control of seizures originating from a specific brain region. - Adjunctive epilepsy therapy: improves overall seizure control in patients not fully responsive to other antiepileptics.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Nausea - Headache - Fatigue

Serious or Rare Side Effects: - Cardiac conduction abnormalities (PR interval prolongation) - Suicidal thoughts or behavior - Severe skin reactions such as Stevens‑Johnson syndrome

When prescribing Lacosamide, clinicians should consider several safety aspects.

- Renal impairment: assess renal function and consider dose adjustment. - Hepatic impairment: monitor liver enzymes and adjust as needed. - Cardiac conduction disorders: obtain baseline ECG and monitor PR interval. - Pregnancy: risk unknown; use only if benefits outweigh potential risks. - Concomitant CNS depressants: monitor for enhanced sedation. - Store at room temperature: keep in original container, protect from moisture and light.

Lacosamide can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels. - Drugs that prolong PR interval (e.g., carbamazepine, quinidine): risk of cardiac conduction delay.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs: may require dose adjustments. - Alcohol: can enhance CNS depression. - Hormonal contraceptives: may reduce efficacy of contraceptive.